NeoGenomics, Inc. $NEO Stock Holdings Lifted by GW&K Investment Management LLC

GW&K Investment Management LLC lifted its position in NeoGenomics, Inc. (NASDAQ:NEO) by 7.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,238,767 shares of the medical research company’s stock after acquiring an additional 155,882 shares during the period. GW&K Investment Management LLC owned about 1.73% of NeoGenomics worth $26,328,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in NEO. Aster Capital Management DIFC Ltd increased its position in shares of NeoGenomics by 42.5% in the third quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock worth $26,000 after acquiring an additional 997 shares in the last quarter. First Horizon Corp increased its position in shares of NeoGenomics by 52.6% in the fourth quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock worth $30,000 after acquiring an additional 865 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of NeoGenomics in the second quarter worth approximately $32,000. GAMMA Investing LLC increased its position in shares of NeoGenomics by 68.2% in the fourth quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock worth $42,000 after acquiring an additional 1,460 shares in the last quarter. Finally, Captrust Financial Advisors purchased a new position in shares of NeoGenomics in the second quarter worth approximately $75,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics Stock Performance

NEO stock opened at $11.28 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.06 and a current ratio of 4.42. The stock has a market cap of $1.47 billion, a P/E ratio of -14.65 and a beta of 1.82. The firm has a 50 day simple moving average of $8.93 and a 200 day simple moving average of $10.32. NeoGenomics, Inc. has a 52 week low of $4.72 and a 52 week high of $13.74.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, April 28th. The medical research company reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. The business had revenue of $186.67 million during the quarter, compared to analysts’ expectations of $184.54 million. NeoGenomics had a negative net margin of 13.30% and a negative return on equity of 2.80%. NeoGenomics’s quarterly revenue was up 11.3% on a year-over-year basis. Research analysts anticipate that NeoGenomics, Inc. will post -0.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on NEO shares. Piper Sandler lifted their target price on shares of NeoGenomics from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 24th. UBS Group reissued a “hold” rating on shares of NeoGenomics in a research report on Wednesday, February 18th. Benchmark raised NeoGenomics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Wednesday, April 29th. William Blair reissued a “market perform” rating on shares of NeoGenomics in a research report on Monday, March 16th. Finally, Leerink Partners raised NeoGenomics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $12.00 to $25.00 in a research report on Wednesday, April 29th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $13.86.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.